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Purpose of the study
The efficacy and tolerability of nucleoside reverse tran-
scriptase inhibitors (NRTIs) are well characterized. In this
analysis we examined the cost-effectiveness of once-daily
tenofovir/emtricitabine [TDF/FTC] compared with twice-
daily zidovudine/lamivudine [ZDV/3TC] and once-daily
abacavir/lamivudine [ABC/3TC] in treatment-naïve HIV-
infected adults in the US.
Methods
Lifetime costs and health outcomes for a treatment-naïve
cohort were modeled using a Markov framework with six
health states based on CD4 cell-count ranges. Efficacy
data for first-line therapy were based on 144-week results
of Study 934 comparing TDF/FTC + efavirenz [EFV] with
ZDV/3TC + EFV and normalized 48-week results of Study
CNA30024 comparing ABC/3TC + EFV with ZDV/3TC +
EFV. Immune response data were used to calculate transi-
tion probabilities between the CD4-based health states.
Individuals with viral loads higher than 400 copies/mL
switched to second-line therapy at rates estimated over
time using exponential functions fitted to trial data. Costs
and efficacy for subsequent therapy lines were based on
likely baskets of second-line, third-line, and non-suppres-
sive therapy regimens. Costs for antiretroviral drugs were
based on 2008 wholesale acquisition costs. Utility values,
mortality rates, and costs for other medical resources were
obtained from published sources. Adverse events
observed in Studies 934 and CNA30024 were accounted
for in modeled costs and outcomes. Base-case results were
tested in one-way and probabilistic sensitivity analyses
(PSA).
Summary of results
On average, individuals using TDF/FTC were predicted to
remain on first-line therapy for 6.0 years, accrue total life-
time costs of $620,673, and experience 14.22 quality-
adjusted life-years (QALYs) compared with 4.9 years,
$631,436 and 13.89 QALYs for those using ZDV/3TC, and
5.0 years, $629,143 and 14.10 QALYs for those using
ABC/3TC. One-way sensitivity analysis predicted TDF/
FTC to be cost saving for almost all parameter ranges and
scenarios tested; PSA showed TDF/FTC was likely to be
cost saving.
Conclusion
TDF/FTC was predicted to be both more effective and cost
saving compared with ZDV/3TC and ABC/3TC in treat-
ment-naïve adults with HIV infection in the US. Cost sav-
ings were largely due to avoidance of more expensive
subsequent lines of therapy and lower costs associated
with adverse events and disease-related resource use.
Results were robust to parameter uncertainty and mode-
ling assumptions.
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